BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Liang J, Deng X, Lin ZX, Zhao LC, Zhang XL. Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis. World J Gastroenterol 2009; 15(36): 4529-4537 [PMID: 19777611 DOI: 10.3748/wjg.15.4529]
URL: https://www.wjgnet.com/1007-9327/full/v15/i36/4529.htm
Number Citing Articles
1
Carlos Pérez-Monter, Aldo Torre-Delgadillo. Astrocyte - Physiology and Pathology2018;  doi: 10.5772/intechopen.72506
2
P. D. J. Dunne, J. A. Fallowfield. Editorial: getting bullish about portal hypertension—chronic treatment with oral taurine?Alimentary Pharmacology & Therapeutics 2018; 47(4): 533 doi: 10.1111/apt.14444
3
Harikumar Nair, Annalisa Berzigotti, Jaime Bosch. Emerging therapies for portal hypertension in cirrhosisExpert Opinion on Emerging Drugs 2016; 21(2): 167 doi: 10.1080/14728214.2016.1184647
4
Xing-Qiu Liang, Jian Liang, Xiao-Fang Zhao, Xin-Yuan Wang, Xin Deng. Integrated network analysis of transcriptomic and protein-protein interaction data in taurine-treated hepatic stellate cellsWorld Journal of Gastroenterology 2019; 25(9): 1067-1079 doi: 10.3748/wjg.v25.i9.1067
5
Eric Felli, Yelidousi Nulan, Sonia Selicean, Cong Wang, Jordi Gracia-Sancho, Jaume Bosch. Emerging Therapeutic Targets for Portal HypertensionCurrent Hepatology Reports 2023; 22(1): 51 doi: 10.1007/s11901-023-00598-4
6
Qinglu Xu, Tianzhu Luan, Songbin Fu, Jian Yang, Chao Jiang, Fangfang Xia. Effects of Pitavastatin on the Expression of VCAM‐1 and its Target Gene miR‐126 in Cultured Human Umbilical Vein Endothelial CellsCardiovascular Therapeutics 2014; 32(5): 193 doi: 10.1111/1755-5922.12081
7
R. Schwarzer, D. Kivaranovic, M. Mandorfer, R. Paternostro, D. Wolrab, B. Heinisch, T. Reiberger, M. Ferlitsch, C. Gerner, M. Trauner, M. Peck‐Radosavljevic, A. Ferlitsch. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertensionAlimentary Pharmacology & Therapeutics 2018; 47(1): 86 doi: 10.1111/apt.14377
8
Susana G. Rodrigues, Yuly P. Mendoza, Jaime Bosch. Investigational drugs in early clinical development for portal hypertensionExpert Opinion on Investigational Drugs 2022; 31(8): 825 doi: 10.1080/13543784.2022.2095259
9
Gangadhar Surabhi, Shubhajit Dhara, Anusree Maneesh, Kajal Chakraborty, Lokanatha Valluru, Sambasiva Reddy Chenchula. Polygalacto-fucopyranose from marine alga as a prospective antihypertensive leadInternational Journal of Biological Macromolecules 2021; 183: 589 doi: 10.1016/j.ijbiomac.2021.04.140
10
Jordi Gracia-Sancho, Giusi Marrone, Anabel Fernández-Iglesias. Hepatic microcirculation and mechanisms of portal hypertensionNature Reviews Gastroenterology & Hepatology 2019; 16(4): 221 doi: 10.1038/s41575-018-0097-3
11
Ji-Yao Sheng, Zi-Fan Meng, Qiao Li, Yong-Sheng Yang. Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertensionHepatobiliary & Pancreatic Diseases International 2024; 23(1): 4 doi: 10.1016/j.hbpd.2023.08.003
12
Hongyue Ma, Jiejun Jiang, Junfeng Zhang, Jing Zhou, Anwei Ding, Gaohong Lv, Huiqin Xu, Fenqiang You, Zhen Zhan, Jinao Duan. Protective effect of taurine on cardiotoxicity of the bufadienolides derived from toad (Bufo bufo gargarizansCanto) venom in guinea-pigsin vivoandin vitroToxicology Mechanisms and Methods 2012; 22(1): 1 doi: 10.3109/15376516.2011.583295
13
Marina Vilaseca, Sergi Guixé-Muntet, Anabel Fernández-Iglesias, Jordi Gracia-Sancho. Advances in therapeutic options for portal hypertensionTherapeutic Advances in Gastroenterology 2018; 11 doi: 10.1177/1756284818811294
14
Alfonsina Milito, Mariarita Brancaccio, Giuseppe D’Argenio, Immacolata Castellano. Natural Sulfur-Containing Compounds: An Alternative Therapeutic Strategy against Liver FibrosisCells 2019; 8(11): 1356 doi: 10.3390/cells8111356
15
Can-Jie Guo, Qin Pan, Hua Xiong, Yu-Qi Qiao, Zhao-Lian Bian, Wei Zhong, Li Sheng, Hai Li, Lei Shen, Jing Hua, Xiong Ma, Jing-Yuan Fang. Dynamic expression of miR‐126∗ and its effects on proliferation and contraction of hepatic stellate cellsFEBS Letters 2013; 587(23): 3792 doi: 10.1016/j.febslet.2013.09.047
16
Johannes Wiegand, Florian van Bömmel, Andrés Duarte-Rojo, José Altamirano, Juan G. Abraldes, Augusto Villanueva, Thomas Berg. Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015Journal of Hepatology 2016; 64(6): 1428 doi: 10.1016/j.jhep.2016.02.020
17
Can-Jie Guo, Qin Pan, Hua Xiong, Yu-Qi Qiao, Zhao-Lian Bian, Wei Zhong, Li Sheng, Hai Li, Lei Shen, Jing Hua, Xiong Ma. Therapeutic Potential of MicroRNA: A New Target to Treat Intrahepatic Portal Hypertension?BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/797898
18
Philipp Schwabl, Wim Laleman. Novel treatment options for portal hypertensionGastroenterology Report 2017; 5(2): 90 doi: 10.1093/gastro/gox011
19
Asbjørn Gildberg, Jan Arne Arnesen, Bjørn-Steinar Sæther, Jaran Rauø, Even Stenberg. Angiotensin I-converting enzyme inhibitory activity in a hydrolysate of proteins from Northern shrimp (Pandalus borealis) and identification of two novel inhibitory tri-peptidesProcess Biochemistry 2011; 46(11): 2205 doi: 10.1016/j.procbio.2011.08.003
20
Tomoko Tadokoro, Asahiro Morishita, Tsutomu Masaki. Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNAInternational Journal of Molecular Sciences 2021; 22(15): 8139 doi: 10.3390/ijms22158139